	US 11,952,412 B2
	Exosome-based anticancer agent
Eun-ee Koh, Seoul (KR); Eun Jung Lee, Seoul (KR); Yoo Soo Yang, Seoul (KR); and In-San Kim, Seoul (KR)
Assigned to SHIFTBIO, Seoul (KR)
Filed by SHIFTBIO, Seoul (KR)
Filed on Apr. 3, 2022, as Appl. No. 17/712,155.
Application 17/712,155 is a continuation of application No. 16/475,052, granted, now 11,319,360, previously published as PCT/KR2017/015784, filed on Dec. 29, 2017.
Claims priority of application No. 10-2016-0182573 (KR), filed on Dec. 29, 2016.
Prior Publication US 2022/0251170 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/71 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C12N 9/12 (2006.01)

CPC C07K 14/71 (2013.01) [A61P 35/00 (2018.01); C12N 9/12 (2013.01); C12Y 207/10001 (2013.01); A61K 38/00 (2013.01); C07K 2319/03 (2013.01)]

17 Claims

9. A pharmaceutical composition comprising:

a recombinant exosome having Surfactant protein A, Surfactant protein D, an anti-CD47 antibody, or any combination thereof that is clustered in the form of a lipid raft on the surface of the recombinant exosome, wherein the recombinant exosome binds to a surface protein of a cancer cell more than a naturally occurring exosome does;

an anticancer agent; and

a pharmaceutically acceptable carrier.